Author

Ray Manneh Kopp

OpenAlex ID: A5128845020

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

2026 · Robert J Motzer, Ray McDermott, et al. · The Lancet · 7

Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors

2026 · Philipp Mandel, Mike Wenzel, et al. · European Urology Open Science · 6

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)

2026 · Veronica Mollica, Francesco Massari, et al. · Cancer Immunology Immunotherapy · 5

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study

2026 · Philipp Cornelius Mandel, Mike Wenzel, et al. · European Urology Oncology · 4

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project

2026 · Alessandro Rizzo, Francesco Ciccimarra, et al. · BMC Cancer · 3

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

2026 · Lorena Incorvaia, Daniele Santini, et al. · International Journal of Cancer · 1

Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)

2026 · Patrizia Giannatempo, Shilpa Gupta, et al. · Scientific Reports · 1

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)

2026 · Evelyn L. Beas-Lozano, Sarah Scagliarini, et al. · Frontiers in Immunology · 1

Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey

2026 · Yuksel Urun, Kannan Sridharan, et al. · The Oncologist

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial

2026 · Ignace Vergote, David Cibula, et al. · The Lancet Oncology

34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study

2026 · Manuela Schmidinger, Daniel Y C Heng, et al. · The Oncologist

Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study

2026 · Patricia Rioja, Carolina Passarella, et al. · Urologic Oncology Seminars and Original Investigations

Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration–Sensitive Prostate Cancer

2026 · Federico Losco, Nicolas Villareal Trujillo, et al. · Clinical Genitourinary Cancer

Works count: 14

Citation count: 35

H-index: 4

I10-index: